The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy
Clinics
; 67(9): 1063-1069, Sept. 2012. ilus, tab
Artigo
em Inglês
| LILACS
| ID: lil-649387
Biblioteca responsável:
BR1.1
ABSTRACT
OBJECTIVE:
Chagas' disease has spread throughout Latin America because of the high rate of migration among these countries. Approximately 30% of Chagas' patients will develop cardiomyopathy, and 10% of these will develop severe cardiac damage leading to heart failure. Beta-blockade improves symptoms and survival in heart failure patients; however, its efficacy has not been well established in Chagas' disease. We evaluated the role of carvedilol in cardiac remodeling and mortality in a Chagas' cardiomyopathy animal model.METHODS:
We studied Trypanosoma cruzi infection in 55 Syrian hamsters that were divided into three groups control (15), infected (20), and infected + carvedilol (20). Animals underwent echocardiography, electrocardiography, and morphometry for collagen evaluation in ventricles stained with picrosirius red.RESULTS:
The left ventricular diastolic diameter did not change between groups, although it was slightly larger in infected groups, as was left ventricular systolic diameter. Fractional shortening also did not change between groups, although it was slightly lower in infected groups. Collagen accumulation in the interstitial myocardial space was significantly higher in infected groups and was not attenuated by carvedilol. The same response was observed in the perivascular space. The survival curve showed significantly better survival in the control group compared with the infected groups; but no benefit of carvedilol was observed during the study. However, in the acute phase (up to 100 days of infection), carvedilol did reduce mortality.CONCLUSION:
Carvedilol did not attenuate cardiac remodeling or mortality in this model of Chagas' cardiomyopathy. The treatment did improve survival in the acute phase of the disease.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
Doença Cardiovascular
/
Outras Doenças Circulatórias
Base de dados:
LILACS
Assunto principal:
Propanolaminas
/
Carbazóis
/
Cardiomiopatia Chagásica
/
Antagonistas Adrenérgicos beta
/
Remodelação Ventricular
Tipo de estudo:
Estudo de avaliação
/
Estudo prognóstico
Limite:
Animais
Idioma:
Inglês
Revista:
Clinics
Assunto da revista:
Medicina
Ano de publicação:
2012
Tipo de documento:
Artigo
/
Documento de projeto
País de afiliação:
Brasil
Instituição/País de afiliação:
Universidade de São Paulo/BR